Biomarker can be defined as a naturally occurring gene, molecule, or a characteristic that can be quantitatively analyzed and assessed as an indicator of a pathogenic, normal biological, or a pharmacological response to a therapeutic intervention. Biomarkers are identified by diagnostic processes, assays, and certain interventions. Any anomaly identified in the biomarker indicates the presence of a disease such as cancer; thus, this process can be quantified and interrelated with disease, health, or drug treatment. The cancer biomarkers market report covers revenue generated from sales of instruments used in cancer biomarker diagnostic procedures. However, applications of cancer biomarkers in research, clinical trials, drug development, drug validation, risk assessment, and drug formulation are excluded from the scope of this report. The report also excludes revenue generated from services provided by physicians in the cancer biomarker diagnostics procedures.

CHAPTER 1: INTRODUCTION 

CHAPTER 2: EXECUTIVE SUMMARY 

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY

CHAPTER 5: CANCER BIOMARKERS MARKET, BY BIOMOLECULES

CHAPTER 6: CANCER BIOSENSORS MARKET, BY CANCER TYPE

CHAPTER 7: CANCER BIOMARKER MARKET, BY APPLICATION

CHAPTER 8: CANCER BIOMARKERS MARKET, BY REGION

CHAPTER 9: COMPANY PROFILES